Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements (Details Textual)

v3.20.1
Note 5 - Fair Value Measurements (Details Textual) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2020
Jun. 30, 2019
Jun. 04, 2019
Oct. 31, 2018
Aug. 01, 2018
Jul. 02, 2018
Business Combination, Liabilities Arising from Contingencies, Amount Recognized       $ 14.6      
Exosome Diagnostics, Inc [Member]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 325.0 $ 325.0          
Business Combination, Liabilities Arising from Contingencies, Amount Recognized           $ 3.8  
QT Holdings Corporation [Member]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 51.0 51.0          
Business Combination, Liabilities Arising from Contingencies, Amount Recognized             $ 5.3
B-MoGen [Member]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 38.0 38.0   38.0      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized       $ 5.5      
Embedded Derivative Financial Instruments [Member]              
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 1.3 2.1          
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member]              
Derivative, Notional Amount         $ 380.0    
CCXI [Member]              
Investments, Total 7.6 7.6 $ 18.8        
CCXI [Member] | Warrant to Purchase Equity Shares [Member]              
Warrants and Rights Outstanding $ 5.6 $ 5.6